font size
Sign in


Broadening the Omics
to Personalize
Cancer Therapy

Podcast: August 4, 2014

The decision-making process for cancer treatments is growing more sophisticated with the broadening of data used to determine the best course of treatment for an individual patient. Perthera, a precision cancer therapy company, is leveraging recent scientific breakthroughs to perform a complete molecular analysis of a patient’s cancer to determine the best therapies and drug trials to treat each patient’s unique cancer. We spoke to Dendy Young, chairman of Perthera, about the company, the benefits of looking beyond the genetics of tumors to determine the course of treatment to use for a patient, and whether these personalized medicine approaches in cancer will take hold in other disease areas. Read More
Todays Stories
Podcast Breaking through the Sequencing Bottleneck

Pieter van Rooyen, CEO of Edico Genome, discusses the genomics computing bottleneck, how the company plans to use the $10 million in funding it just raised, and what the implications of a dramatic reduction in time and cost will have on how sequencing is used.

By the numbers Five Life Sciences Companies Price IPOs Below Target Midpoint

While life sciences IPOs continue to get done, it seems that most must now slash their target price to go public. The five life sciences companies that completed initial public offerings during the fourth week of July discounted their shares 26.4 percent on average from the midpoint of their target range to get their deals done.